Acta dermato-venereologica最新文献

{"title":"Successful Treatment of Crohn Disease and Concomitant Alopecia Totalis with Upadacitinib: Case Report and Systematic Review of the Literature.","authors":"Yuki M F Andersen, Farzad Seyed-Alinaghi, Malene F Kristiansen, Simon F Thomsen","doi":"10.2340/actadv.v106.adv-2025-0156","DOIUrl":"10.2340/actadv.v106.adv-2025-0156","url":null,"abstract":"","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13093871/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147727973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe Ulceronecrotic Evolution during Mogamulizumab Treatment in a Patient with Primary Cutaneous Peripheral T-cell Lymphoma.","authors":"Quentin Samaran, Marilou Duboëlle, Anaïs Marque, Virginie Bres, Olivier Dereure","doi":"10.2340/actadv.v106.adv-2025-0279","DOIUrl":"10.2340/actadv.v106.adv-2025-0279","url":null,"abstract":"","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13094340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147728038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex Differences in Loss in Life Expectancy in Primary Cutaneous Melanoma, a Swedish Cohort Study.","authors":"Anna Oksanen, Elisavet Syriopoulou, Kari Nielsen, Hanna Eriksson, Therese Andersson","doi":"10.2340/actadv.v106.adv-2025-0227","DOIUrl":"10.2340/actadv.v106.adv-2025-0227","url":null,"abstract":"<p><p>Sex differences in cutaneous melanoma (CM) survival are pronounced. It is unclear how these differences impact the loss in life expectancy (LLE). A population-based cohort from the Swedish Melanoma registry was used to analyze sex differences in life expectancy (LE) and LLE following a CM diagnosis. The cohort included 12 ,893 men and 12 ,572 women aged 40 years or above diagnosed with a first invasive CM in Sweden between 2000 and 2014. The average remaining LE at CM diagnosis was 15.45 years (95% CI 15.21, 15.7) for men and 20.14 years (95% CI 19.89, 20.43) for women, and the LLE was 2.95 years (95% CI 2.70, 3.19) and 2.4 years (95% CI 2.11, 2.67), respectively. If men had the same relative survival as women, the average LE for men would instead be 17.33 years (95% CI 17.03, 17.65) and the LLE 1.07 years (95% CI 1.07, 1.38). Men lose more years due to CM than women. Baseline age, stage or location are not sufficient to explain the sex differences.</p>","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147727995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Exploratory Study to Identify Factors Associated with Recurrence of Generalized Pustular Psoriasis Flares in Adult Patients in Japan.","authors":"Akimichi Morita, Yukari Okubo, Ryuhei Okuyama, Yoko Mizutani, Nobuo Kanazawa, Atsushi Otsuka, Takuya Miyagi, Masao Shionoya, Reina Mizuno, Morihisa Saitoh, Shinichi Imafuku","doi":"10.2340/actadv.v106.adv-2025-0024","DOIUrl":"10.2340/actadv.v106.adv-2025-0024","url":null,"abstract":"<p><p>Generalized pustular psoriasis (GPP) is a rare, systemic inflammatory disease characterized by a heterogeneous and often unpredictable clinical course involving chronic symptoms and recurrent flares. Due to the rarity of GPP, our understanding of factors associated with flare recurrence remains unclear. Using an existing data set of adult patients with GPP in Japan, we performed univariate and multivariate analyses to investigate potential factors related to GPP flare recurrence, including patient demographics,  treatment and severity of baseline flare. In total, 150 patients with a baseline flare were included in this analysis; 27.3% (n=41) experienced flare recurrence during the follow-up period (mean duration: 4.16 years). For the overall population, 56.0% of patients were male (n=84), the mean age at baseline was 55.5 years, and the mean body mass index was 24.3 kg/m2. Based on the Cox proportional hazards model, comorbid diabetes mellitus, a fever of ≥38.5°C at baseline flare, experience of flare(s) prior to baseline and certain respiratory infections were associated with a higher risk of flare recurrence, similar to previously published findings. These results could help identify patients at risk of GPP flares; however, clinically applicable prediction of GPP flares requires further research in a wider population.</p>","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13093872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147728021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Impact of Fatigue and Sleep Disturbance in Hidradenitis Suppurativa: Perspectives from Patients and Healthcare Professionals.","authors":"Barry M McGrath, Donna Atherton, Phil Brady, Marie-France Bru-Daprés, Jennifer L Hsiao, Silvia Lobo, Latoya Palmer, Giuseppina Pintori, Jacek C Szepietowski, Mei Go, Ivette Alarcon, John R Ingram","doi":"10.2340/actadv.v106.adv-2025-0179","DOIUrl":"10.2340/actadv.v106.adv-2025-0179","url":null,"abstract":"<p><p>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that affects physical, social and emotional aspects of life for people living with HS (plwHS). Although many plwHS consider pain the most bothersome symptom, fatigue and sleep disturbance are underexplored in research and rarely discussed in clinical practice. This article shares perspectives from plwHS and people working with patients, including healthcare professionals (HCPs), from Europe and North America, on the impact of HS-related fatigue and sleep disturbance on quality of life (QoL). Fatigue was described as a debilitating symptom affecting QoL, with HCPs often noting that plwHS were unaware of the full impact of fatigue until treatment improved their HS symptoms. Sleep disturbance was mainly attributed to HS-related pain, pruritus and lesion drainage, with sleep deficits accumulating over time. The strain of HS impacted personal relationships, with plwHS expressing less interest in social interactions or intimate relationships, leading to feelings of guilt, failure, isolation and reduced self-esteem. Fatigue and sleep disturbance also affected work productivity, and consequently, career progression and financial stability. Recognizing the multifaceted HS symptoms, providing reasonable adjustments in the workplace, encouraging open dialogue with HCPs and measuring fatigue with a validated instrument could help improve QoL of plwHS.</p>","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13086963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147697160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Xeligekimab Compared to Other IL-17A Inhibitors for Chinese Patients with Moderate-to-severe Plaque Psoriasis: A Matching-adjusted Indirect Comparisons.","authors":"Yangfeng Ding, Weida Liu","doi":"10.2340/actadv.v106.adv-2025-0183","DOIUrl":"10.2340/actadv.v106.adv-2025-0183","url":null,"abstract":"<p><p>Direct comparative evidence between IL-17A inhibitors for plaque psoriasis in Chinese populations remains limited. This study evaluated the comparative effectiveness of Xeligekimab vs Secukinumab and Ixekizumab through matchingadjusted indirect comparisons (MAICs). Individual patient data from the Xeligekimab trial (N=281) were weighted to match baseline characteristics from Chinese trials of Secukinumab (N=221) and Ixekizumab (N=176/92). Matching variables were determined following NICE and EUnetHTA MAIC guidelines, incorporating prognostic factors identified through multivariate regression. Primary endpoints included PASI 75/90/100 achievement at weeks 12, 52 and 60. At week 12, Secukinumab showed numerically higher PASI 75 (97.7% vs 93.0%, p=0.052) without statistical significance, while other endpoints were comparable (all p>0.05). At week 52, Xeligekimab showed significantly higher PASI 100 achievement (57.8% vs 42.1%, p=0.005) and DLQI 0/1 (68.8% vs 47.5%, p<0.001) vs Secukinumab. At week 60, Xeligekimab maintained significantly higher PASI 75 vs Ixekizumab (92.6% vs 76.1%, p<0.001) with lower infection rates during induction period (7.9% vs 34.7%, p<0.001) and maintenance period (22.4% vs 56.5%, p<0.001). This MAIC provides hypothesis-enerating evidence that Xeligekimab may offer advantages in specific long-term efficacy endpoints and safety outcomes, requiring confirmation in direct randomized controlled trials.</p>","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13086962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147697126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis).","authors":"Elena Pezzolo, Rossi Mariateresa, Raul Armando Luyo Saboya, Piergiorgio Malagoli, Alessandra Narcisi, Silvia M Ferrucci, Giampiero Girolomoni, Anna Balato, Flavia Manzo Margiotta, Claudio Sciarrone, Caterina Foti, Massimo Gola, Maria Esposito, Maddalena Napolitano, Carlotta Gurioli, Michela Ortoncelli, Francesca Satolli, Maria L Musumeci, Paola Savoia, Fabrizio Amoruso, Anna G Burroni, Cristina Beatrice Spigariolo, Piergiacomo Calzavara-Pinton, Antonio Costanzo, Luigi Gargiulo, Francesca Barei, Martina Maurelli, Marco Romanelli, Federica Veronese, Benedetta Tirone, Maria C Fargnoli, Cataldo Patruno, Simone Ribero, Marco Vaccino, Luigi Naldi","doi":"10.2340/actadv.v106.adv-2025-0193","DOIUrl":"10.2340/actadv.v106.adv-2025-0193","url":null,"abstract":"<p><p>Abrocitinib, an oral selective Janus kinase 1 inhibitor, is approved for the treatment of moderate-tosevere atopic dermatitis (AD) in adults, but realworld evidence remains limited. We retrospectively collected data from 187 adult patients (mean age:37.9 years; 60.4% male), with AD and up to oneyear exposure to abrocitinib either 100 or 200 mg, between 2023 and 2025 across 22 Italian dermatology centres. Nearly half of patients were bio-experienced and 80 % had difficult-to-treat areas. Beginning at week 8, with either 100 (59%) or 200 mg, 52 % achieved Investigator Global Assessment 0/1, significantly increasing to 88 % at week 52. Similarly, Eczema Area and Severity Index (EASI) and itch had significantly higher 1-year response: increasing from 27.8% and 34.7%, respectively, at week 8, 79.6 % achieved EASI-90 and 73.5% reached Peak Pruritus-Numerical Rating Scale 0/1. Minimal disease activity, a stringent composite endpoint, was met by 18 % at week 8 and by 66 % at week 52. Safety was good, with mild adverse events mostly including abdominal pain, upper respiratory infections and headache. The 100 mg dose had a significantly better safety profile, with efficacy similar to 200 mg. These data confirm the efficacy and safety of abrocitinib, with early, progressive clinical benefits sustained through 1 year.</p>","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13077735/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147687531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atypical Prurigo Pigmentosa Following Ketogenic Diet: Successful Treatment with Doxycycline and Tofacitinib.","authors":"Xiaoxiao Zhang, Zhangyu Bu","doi":"10.2340/actadv.v106.adv-2026-0465","DOIUrl":"10.2340/actadv.v106.adv-2026-0465","url":null,"abstract":"","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13079266/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147687606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concurrent Drug-induced Rowell Syndrome and Acute Generalized Exanthematous Pustulosis.","authors":"Yu-Han Alice Hsu, Kuan-Yu Chu, Cheng-Che Eric Lan","doi":"10.2340/actadv.v106.adv-2026-0400","DOIUrl":"10.2340/actadv.v106.adv-2026-0400","url":null,"abstract":"","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13084623/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147687575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic Inflammatory Indexes as Easy-to-Use Markers for Monitoring Psoriasis and Hidradenitis Suppurativa.","authors":"Eugenia Veronica Di Brizzi, Dario Buononato, Alfonso Luca Falco, Elisabetta Fulgione, Stefano Caccavale, Giuseppe Argenziano, Anna Balato","doi":"10.2340/actadv.v106.43695","DOIUrl":"10.2340/actadv.v106.43695","url":null,"abstract":"","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":"adv43695"},"PeriodicalIF":3.7,"publicationDate":"2026-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13069474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147637602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}